Women who take a common type of medication to control their blood pressure are not at increased risk of developing breast cancer due to the drug, according to new study by researchers at the Intermountain Medical Center Heart Institute in Murray, Utah.
New evidence that suggests patients with a history of adverse reaction to the blood thinner heparin may be ready for urgent heart surgery sooner with a combination of appropriate blood screenings and therapeutic plasma exchange.
A team of researchers from Johns Hopkins Medicine has discovered a receptor on blood vessels that causes the vessel to relax in response to light, making it potentially useful in treating vascular diseases. In addition, researchers discovered a previously unknown mechanism by which blood vessel function is regulated through light wavelength.
Researchers at the University of California, San Diego School of Medicine describe the surprising and crucial involvement of a pro-inflammatory signaling protein in the creation of hematopoietic stem cells (HScs) during embryonic development, a finding that could help scientists to finally reproduce HSCs for therapeutic use.
Interim data from an ongoing Phase I/II trial of Actimab-A, an innovative targeted payload immunotherapy, demonstrated a number of positive findings, including extension of overall survival and significant reductions in bone marrow blasts in older patients with newly diagnosed Acute Myeloid Leukemia (AML).
Researchers at UC Davis have found that the drug bortezomib effectively treats chronic graft-versus-host disease (GVHD), a common and debilitating side effect from allogeneic hematopoietic stem cell transplants. The trial showed that bortezomib provides better outcomes than existing treatments and does not impair the immune response against residual cancer cells, or the graft-versus-tumor effect (GVT).
A solitary cell containing a unique abnormality can result in certain types of blood cancers known as myeloproliferative neoplasms (MPN), according to researchers in Switzerland. The results open new opportunities to examine single mutant cells and follow tumor initiation and progression of human MPN cancers.
UT Southwestern Medical Center researchers seeking novel treatments for anemia found that giving acetate, the major component of household vinegar, to anemic mice stimulated the formation of new red blood cells.
An international team of scientists has identified a gene mutation that causes aplastic anemia, a serious blood disorder in which the bone marrow fails to produce normal amounts of blood cells. The gene regulates telomeres on the ends of chromosomes.
A new molecule, the first of its kind, allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.
In an analysis of the results of nearly 50 randomized trials that examined treatments of venous thromboembolisms (blood clot in a vein), there were no significant differences in clinical and safety outcomes associated with most treatment strategies when compared with the low-molecular-weight heparin-vitamin K antagonist combination, according to a study in the September 17 issue of JAMA.
Sickle cell disease had been considered a pediatric ailment since people with it generally didn’t live to adulthood. As pediatricians, we’ve done a good job caring for our patients – 95% now live to their 20th birthday. Unfortunately, when our patients prepare to leave the pediatric system, a smooth transition to adult healthcare is lacking.
A simple point-of-care testing device for anemia could provide more rapid diagnosis of the common blood disorder and allow inexpensive at-home self-monitoring of persons with chronic forms of the disease.
More than one-quarter of young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and may benefit from drugs widely used to treat other types of leukemia that are more common in adults, according to multi-institutional research led by St. Jude Children’s Research Hospital investigators.
A Johns Hopkins Sickle Cell Disease researcher and patient led a study of other Sickle Cell patients and the connection between their adherence to medical advice and their perceived discrimination by the healthcare system.
The National Heart, Lung, and Blood Institute (NHLBI) has released the first comprehensive, evidence-based guidelines for management of sickle cell disease from birth to end of life.
Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy. The findings, reported by doctors at Wake Forest Baptist Medical Center, are published in the current online edition of the journal Clinical Cancer Research.
Accidents as minor as a slip of the knife while chopping onions can turn dangerous for patients with hemophilia, who lack the necessary proteins in their blood to stem the flow from a wound.
John Wood, MD, PhD, and colleagues are looking into how the body regulates blood flow to the muscles and brain in patients with sickle cell trait (SCT). They hope to determine specific factors that put certain SCT athletes at risk for life-threatening complications during vigorous exercise.
A Penn Medicine-developed drug has received orphan status in Europe this week for the treatment of paroxysmal nocturnal hemoglobinuria, a rare, life-threatening disease that causes anemia due to destruction of red blood cells and thrombosis.
Monthly blood transfusions can substantially reduce the risk of recurrent strokes in children with sickle cell disease (SCD) who have already suffered a silent stroke, according to the results of an international study by investigators at the Johns Hopkins Children’s Center, Vanderbilt University and 27 other medical institutions.
Vanderbilt-led research, as part of an international, multicenter trial, found regular blood transfusion therapy significantly reduces the recurrence of silent strokes and strokes in children with sickle cell anemia who have had pre-existing silent strokes, according to study results released today in the New England Journal of Medicine (NEJM).
Monthly blood transfusions reduce the risk of stroke in young patients with sickle cell anemia, scientists report Aug. 20 in The New England Journal of Medicine.
Scientists have altered key biological events in red blood cells, causing the cells to produce a form of hemoglobin normally absent after the newborn period. This approach may lead to a novel treatment for sickle cell disease.
In what is believed to be the largest genetic analysis of what triggers and propels progression of tumor growth in a common childhood blood cancer, researchers at NYU Langone Medical Center report that they have identified a possible new drug target for treating the disease.
Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead to severe skeletal muscle wasting and, in turn, limb amputation.
Research derived from early national experience of liver transplantation has shown that deceased donor liver transplants offered recipients better survival rates than living donor liver transplants, making them the preferred method of transplantation for most physicians. Now, the first data-driven study in over a decade disputes this notion. Penn Medicine researchers found that living donor transplant outcomes are superior to those found with deceased donors with appropriate donor selection and when surgeries are performed at an experienced center. The research is published this week in the journal Hepatology.
Researchers used x-ray crystallography to publish the first image of prothrombin. The protein’s flexible structure is key to the development of blood-clotting.
The ability to reliably and safely make in the laboratory all of the different types of cells in human blood is one key step closer to reality.
Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia, an Indiana University-led research team has reported.
For the first time, scientists at the UNC School of Medicine have shown that eliminating the enzyme factor XIII reduces the number of red blood cells trapped in a clot, resulting in a 50 percent reduction in the size of the clot.
An antibiotic therapy known to reduce catheter-related bloodstream infections in hemodialysis patients has been shown for the first time to reduce mortality, according to a Henry Ford Health System study.
Use of a lower intensity bone marrow transplantation method showed promising results among 30 patients (16-65 years of age) with severe sickle cell disease, according to a study in the July 2 issue of JAMA.
Researchers at Johns Hopkins Bayview Medical Center used two relatively simple tactics to significantly reduce the number of unnecessary blood tests to assess symptoms of heart attack and chest pain and to achieve a large decrease in patient charges.
Whitehead Institute scientists have genetically and enzymatically modified red blood cells to carry a range of valuable payloads—from drugs, to vaccines, to imaging agents—for delivery to specific sites throughout the body.
Scientists working to make gene therapy a reality have solved a major hurdle: how to bypass a blood stem cell’s natural defenses and efficiently insert disease-fighting genes into the cell’s genome.
A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Researchers at Mayo Clinic released a new study reversing current thought on the treatment of cirrhotic patients with type 2 diabetes. The study found that the continuation of metformin after a cirrhosis diagnosis improved survival rates among diabetes patients.
In an analysis that included data from 16 trials performed over the last 45 years, among patients with pulmonary embolism, receipt of therapy to dissolve the blood clot (thrombolysis) was associated with lower rates of death, but increased risks of major bleeding and intracranial hemorrhage, according to a study in the June 18 issue of JAMA. The authors note that these findings may not apply to patients with low-risk pulmonary embolism.
Every six weeks for the past nine years, Mawasi Belle has been donating blood at Cedars-Sinai’s Blood Donor Services, totaling nearly 80 trips to the medical institution and thousands of pints of blood collected. But for Belle, this selfless act is merely a part of her lifestyle. “My decision to give is easy. If I do not donate, patients with serious blood diseases, like sickle cell anemia, will die.” And Belle is right: Patients with sickle cell disease and other serious blood conditions rely on donors to keep their blood flowing and hearts beating.
Case Western Reserve University researchers have discovered that an existing drug, bortezomib (Velcade), has been shown to help prevent clot development. Lalitha Nayak, MD, an assistant professor of medicine, reports in the June 12 edition of the journal Blood, the anti-thrombotic effects of bortezomib are determined by KLF2.
A UCLA research team has discovered a new hormone called erythroferrone, which regulates the iron supply needed for red blood-cell production.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
A new microfluidic method for evaluating drugs commonly used for preventing heart attacks has found that while aspirin can prevent dangerous blood clots in some at-risk patients, it may not be effective in all patients with narrowed arteries. The study, which involved 14 human subjects, used a device that simulated blood flowing through narrowed coronary arteries to assess effects of anti-clotting drugs.
A Penn research team has defined a possible new way to fight a disease that is currently treatable only with the most expensive drug available for sale in the United States, the strategy, based on the oldest part of the human immune system – called complement.
A vascular disease called fibromuscular dysplasia, which can cause high blood pressure, kidney failure, stroke and other symptoms -- mostly in women -- is “poorly understood by many healthcare providers,” according to a Scientific Statement from the American Heart Association.
Red blood cells are the body’s true shape shifters, perhaps the most malleable of all cell types. While studying how blood clots contract, researchers discovered a new geometry that red blood cells assume, when compressed during clot formation.
T2 Bio and collaborators published data in Blood describing novel clot structure biology detected while testing T2 Bio’s T2HemoStat™ that could help identify stroke and heart attack victims who are less responsive to medications.
Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers. This finding may lead to therapies capable of preventing the progression of these diseases.
Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia A, a serious and costly bleeding condition.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right